The advent of gene expression profiling has identified four subtypes of breast cancer: luminal A, luminal B, HER-2/neu, and basal-like. The basal-like cancers represent approximately 17% to 37% of breast cancers and are biologically aggressive. The lexicon often used by clinicians to describe basal-like cancers is “triple-negative breast cancers” (TNBCs) because TNBCs lack hormone-receptors (ER & PR) and HER-2 expression. Despite their sensitivity to conventional chemotherapy, prognosis remains poor. Recent understanding of TNBC's biology has led to the development and testing of novel therapies with encouraging results.

We invite investigators to contribute original research articles as well as review articles that will further enhance our understanding of this disease. Potential topics include, but are not limited to:

• Recent developments in basal-like subtype and TNBC research
• Advances in our understanding of the biology of basal cancer and TNBC
• Translational research in TNBC
• Identifying biomarkers of TNBC
• Hormonal Therapy and TNBC
• Potential molecular-targeted therapy in the management of TNBC
• The influence of biopsychosocial factors on outcome for patients with TNBC
• The role of poly (ADP-ribose) polymerase (PARP) inhibitors in the management of TNBC
• Global epidemiology of TNBC

Articles published in this special issue will not be subject to the journal's Article Processing Charges.

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijcb/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: